Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance (Encore)
Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance (Encore)
Study Hypothesis: This study is designed as an integral part of the development of new or
 improved features or components of the Bravo® pH Monitoring System and may serve verification
 and validation purposes.

 The study population will include symptomatic patients with known or suspected
 gastroesophageal reflux disease

 Symptomatic patients will undergo invasive procedure, including Bravo capsule delivery,
 positioning and attachment. Confirmation of capsule attachment may be done endoscopically.

 These procedures will serve to evaluate overall system performance in actual clinical setup,
 for instance: ergonomics and performance of delivery device, capsule transmission etc.

 Physician may be asked to provide feedback on the procedure and/or document their activities
 during the procedure.
The study population consists of symptomatic patients with known or suspected gastro
 esophageal reflux disease. The aim of this clinical study is to evaluate Bravo® pH Monitoring
 System.

 Primary objectives

 -  To evaluate usability and functionality of the Bravo® pH Monitoring System and procedure

 -  To evaluate modifications to the Bravo delivery device Primary Endpoints

 1. Evaluate physician subjective assessment questionnaire (appendix 3)

 2. Percentage of successful capsule attachments Patients will undergo standard-of-care
 Bravo pH procedure. Prior to the pH study, the patient should not eat or drink for
 a minimum of 6 hours, according to the standard system instructions.

 -  Bravo procedure may take 48-96 hours

 -  Patients will have a follow-up visit or call, one to two weeks after the procedure

 -  A fluoroscopy procedure may be ordered at physician's discretion to verify capsule
 attachment \ detachment from the patient's esophagus

 Over all expected duration for subject's participation in the study will be a maximum of 1
 month

 Physician may be asked to provide feedback on the procedure usability and functionality and
 to document their activities during the procedure.
Inclusion Criteria:

 1. Subject age ≥ 18 years old

 2. Subject received an explanation about the nature of the study and agrees to provide
 written informed consent.

 3. The subject was referred for pH monitoring procedure to detect acid reflux for at
 least one of the following reasons:

 -  Burning substernal chest pain (heartburn)

 -  Regurgitation of food or stomach contents

 -  Dysphagia

 -  Epigastric pain

 -  Non-erosive reflux disease (NERD)

 -  Chest pain

 -  Cough

 -  Hoarseness

 -  Asthma

 -  Lower pharyngeal irritation, need to clear throat

 Exclusion Criteria:

 1. Subject has a cardiac pacemaker or other implanted electromedical device.

 2. Subject has any condition, which precludes compliance with study and/or device
 instructions.

 3. Women who are either pregnant or nursing at the time of screening, or are of
 child-bearing potential and do not practice medically acceptable methods of
 contraception.

 4. Subject suffers from life threatening conditions

 5. Subject currently participating in another clinical study which may interfere with
 study objectives, per physician discretion

 6. Subject has prior abdominal surgery other than uncomplicated procedures that would be
 unlikely to lead to bowel obstruction based on the clinical judgment of the
 investigator

 7. Subject is schedule to undergo MRI examination within 30 days from pH monitoring
 procedure.

 8. Subject has known bleeding diathesis, strictures, severe esophagitis, varices and or
 obstructions